- Home
- ENLT vs CGON Comparison
ENLT vs CGON Comparison
Compare ENLT & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- CGON
- Stock Information
- Founded
- ENLT 2008
- CGON 2010
- Country
- ENLT Israel
- CGON United States
- Employees
- ENLT N/A
- CGON N/A
- Industry
- ENLT
- CGON
- Sector
- ENLT
- CGON
- Exchange
- ENLT Nasdaq
- CGON NYSE
- Market Cap
- ENLT 1.9B
- CGON 2.2B
- IPO Year
- ENLT 2023
- CGON 2024
- Fundamental
- Price
- ENLT $16.01
- CGON $32.34
- Analyst Decision
- ENLT Buy
- CGON Strong Buy
- Analyst Count
- ENLT 4
- CGON 8
- Target Price
- ENLT $19.00
- CGON $63.88
- AVG Volume (30 Days)
- ENLT 11.0K
- CGON 418.0K
- Earning Date
- ENLT 11-13-2024
- CGON 11-12-2024
- Dividend Yield
- ENLT N/A
- CGON N/A
- EPS Growth
- ENLT N/A
- CGON N/A
- EPS
- ENLT 0.41
- CGON N/A
- Revenue
- ENLT $358,416,000.00
- CGON $684,000.00
- Revenue This Year
- ENLT $428.35
- CGON $411.76
- Revenue Next Year
- ENLT $27.54
- CGON $405.27
- P/E Ratio
- ENLT $38.82
- CGON N/A
- Revenue Growth
- ENLT 47.65
- CGON 258.12
- 52 Week Low
- ENLT $14.09
- CGON $25.77
- 52 Week High
- ENLT $20.00
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- ENLT 50.90
- CGON 34.54
- Support Level
- ENLT $14.96
- CGON $32.53
- Resistance Level
- ENLT $16.48
- CGON $40.47
- Average True Range (ATR)
- ENLT 0.50
- CGON 1.92
- MACD
- ENLT 0.06
- CGON -0.62
- Stochastic Oscillator
- ENLT 71.13
- CGON 11.53
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. It operates across the three largest renewable segments namely solar, wind and energy storage. Geographically, it operates in the United States, Israel and 9 European countries.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.